Sort   by:  
 Page size 
UnknownSafety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials.
Not available
S-EPMC9847543 | biostudies-literature
UnknownReactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
Not available
S-EPMC7216554 | biostudies-literature
UnknownEffect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial.
Not available
S-EPMC11404262 | biostudies-literature
UnknownCamrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.
Not available
S-EPMC11603811 | biostudies-literature
UnknownTolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trial.
Not available
S-EPMC9271434 | biostudies-literature
UnknownYAP drives fate conversion and chemoresistance of small cell lung cancer.
Not available
S-EPMC10938532 | biostudies-literature
UnknownPyrotinib and Nab-Paclitaxel in HER2-Positive Breast Cancer (PANHER Trial): A Prospective, Single-Arm, Phase II Trial.
Not available
S-EPMC12210037 | biostudies-literature
UnknownPhase I study of camrelizumab in patients with advanced solid tumors.
Not available
S-EPMC9892498 | biostudies-literature
UnknownKRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
Not available
S-EPMC5579171 | biostudies-literature
UnknownNeoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.
Not available
S-EPMC11970390 | biostudies-literature
Sort   by:  
 Page size